New Drug Approvals (Original) — October 16, 2026

The FDA granted NME approval to PRITELIVIR (HOVILPR) under Priority Review, a designation signaling significant perceived benefit and a faster 6-month review clock. Peak sales, exclusivity term, and pricing power are NOT_DISCLOSED in the source data.

Bracco received a label expansion approval for IOPAMIDOL under the ISOVUE READI brand. The source data does not specify the expanded indication, patient population, or commercial impact, which limits the strength of the read-through.

The record describes this as a biosimilar approval for Strides Pharma International with a neutral signal, but the approval-type field is FALLBACK and the mix counts show zero biosimilars. Classification must be verified before any originator-side erosion or entrant-side revenue view is taken.

The approval-type metadata for DONEPEZIL HYDROCHLORIDE (FALLBACK, biosimilar summary, zero biosimilar count) is internally inconsistent, creating uncertainty about the regulatory pathway and what the approval actually permits.

PRITELIVIR (HOVILPR) is a new entrant in anti-infective therapy; competitive positioning versus incumbent antivirals cannot be assessed from the approval data alone since indication and comparator details are not provided.

PRITELIVIR (HOVILPR) NME launch by AiCuris Anti-Infective Cures AG following Priority Review approval, representing a potential first-commercial-product inflection for the sponsor.

IOPAMIDOL (ISOVUE READI) label expansion for Bracco extends an existing contrast agent franchise, a lower-risk revenue lever than a new launch.

The three approvals span anti-infective (PRITELIVIR), diagnostic imaging contrast (IOPAMIDOL), and neurology (DONEPEZIL), with no two falling in the same therapeutic area. No cluster signal can be drawn from this period.

{"entity" => "PRITELIVIR (HOVILPR) / AiCuris Anti-Infective Cures AG", "reason" => "NME approval under Priority Review with the highest signal strength (8/10) in this period; commercial metrics are undisclosed.", "trigger" => "Commercial launch date, pricing disclosure, and first payer coverage decisions"}

{"entity" => "DONEPEZIL HYDROCHLORIDE / Strides Pharma International", "reason" => "Conflicting approval classification (biosimilar summary vs. FALLBACK type and zero biosimilar count) requires resolution before the approval is characterized.", "trigger" => "Confirmation of regulatory pathway in FDA databases and any correction to the approval record"}

{"entity" => "IOPAMIDOL (ISOVUE READI) / Bracco", "reason" => "Label expansion with bullish signal but no disclosed indication details.", "trigger" => "Publication of the expanded indication and any associated launch or formulary communications"}